Celsion Corporation
Celsion Receives Orphan Drug Designation for ThermoDox® to Treat Primary Liver Cancer
Published in Medical Letter on the CDC and FDA, April 12th, 2009
Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, announced that the U.S. Food and Drug Administration (FDA ) has granted orphan drug designation for its lead compound, ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer. ThermoDox® is currently being evaluated under a Special Protocol Assessment with the FDA in a 600 patient, global Phase III trial in patients with non-resectable primary liver cancer. Celsion expects to complete patient enrollment for this trial in the first quarter of 2010.
"We are pleased to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Cancer
Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows - Cell Therapy
Scientists at Medical College of Georgia, Medical College report research in cell therapy - Depression
Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents - Kidneys
New kidneys study findings have been published by scientists at Food & Drug Administration - Life Sciences
New life sciences study findings have been reported by researchers at University of California - Life Sciences
Recent studies by R.R. Ratan and co-authors add new data to life sciences findings - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
